Melbourne, Australia, 10th March 2020. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has novel and differentiated findings with its Spingosine-1-Phosphate receptor subtype-1 (S1P1) agonist and lead drug candidate “AK-119” in Phase-1 oral human clinical trial and a new patent application has been filed. The differentiated profile includes the devoid of bradycardia, dyspnoea … Read more